醒脑静注射液辅助治疗血管性痴呆的疗效的Meta分析(1)
摘 要：目的 采用Meta分析方法对醒脑静注射液辅助治疗血管性痴呆的疗效进行系统评价。方法 在国内外多个数据库中检索已经公开发表的关于醒脑静注射液辅助治疗血管性痴呆的相关文献，通过严格文章筛选应用Review Manager5.3进行Meta分析。结果 共纳入12项研究，分析显示，醒脑静注射液辅助治疗血管性痴呆，改善其临床疗效的比值比(OR)合并值为3.80(95%可信区间为2.70～5.30)。MMSE评分疗效标准化均数差(SMD)合并值为4.02(95%可信区间为3.02～5.01)。ADL评分疗效标准化均数差(SMD)合并值为8.0(95%可信区间为3.70～12.29)。HDS评分疗效标准化均数差(SMD)合并值为4.08(95%可信区间为3.46～4.7)。结论 醒脑静注射液在辅助治疗血管性痴呆效果上，患者智力、精神状态、日常生活能力改善明显。其临床疗效显著。
关键词：醒脑静；血管性痴呆；Meta分析
中图分类号：R749.136 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.026
, http://www.100md.com
文章编号：1006-1959(2018)11-0084-05
Meta Analysis of Efficacy of Xingnaojing Injection in Adjuvant Treatment of Vascular Dementia
LI Yu-qin，HUANG Shun-gui，WANG Si-xun，LONG Xiu-ying
(Department of Neurology，the Sixth People's Hospital of Chengdu，Chengdu 610051，Sichuan，China)
Abstract：Objective To evaluate the efficacy of Xingnaojing injection in the treatment of vascular dementia by meta-analysis. Methods The published literatures on the adjuvant treatment of vascular dementia with Xingnaojing injection were searched in many databases at home and abroad，and the meta-analysis was carried out by screening and applying Review Manager 5.3 in strict articles. Results A total of 12 studies were included， and the analysis showed that Xingnaojing injection assisted the treatment of vascular dementia， and the ratio(OR)of the clinical efficacy was 3.80(95% confidence interval 2.70～5.30).The MMSE score was standardized with a mean difference(SMD)with a combined value of 4.02(95% confidence interval 3.02～5.01).The ADL score was standardized with a mean difference(SMD)with a combined value of 8(95% confidence interval 3.70～12.29).The HDS score was standardized with a mean difference(SMD)with a combined value of 4.08(95% confidence interval 3.46～4.7).Conclusion Xingnaojing injection improved the intelligence，mental state and daily living ability of patients with adjuvant treatment of vascular dementia.The clinical effect is remarkable.
, 百拇医药
Key words：Xingnaojing；Vascular dementia；Meta-analysis
隨着社会的发展，人们对痴呆的认识也逐年提高，老年患者中常见疾病-血管性痴呆，现已成为医务人员的研究热点。血管性痴呆在中医诊断中认为属于“呆病”，研究 [1，2]认为具有“醒脑通窍”作用的醒脑静注射液对于急性脑血管病的治疗有着一定的疗效，起着神经保护作用。基于此，醒脑静注射液辅助治疗血管性痴呆也开始研究，为了系统了解醒脑静注射液治疗血管性痴呆的临床疗效，我们采用Meta分析进行评价，希望为临床用药决策提供参考。
1 资料与方法
1.1 文献查找 应用检索词“醒脑静(Xingnaojing)”，“血管性痴呆(Vascular dementia)”检索1990～2017年PubMed、万方数据库、中国学术网期刊全文数据库、中国维普数据库等，查阅原文并进行统计分析。
1.2文献标准 纳入文献病例要求是依据美国精神病协会1994年修订的《精神障碍诊断与统计手册》(DSM-IV)诊断标准或中华医学会神经病学分会《血管性痴呆诊断标准草案》，并经头颅CT或MRI检查提示脑梗死或广泛脑室周围白质病变的患者，排除合并严重器质性疾病及并发症的患者，采用随机对照试验，病例数至少15例以上，不包含个案报道及无对照的临床试验或描述试验，治疗组采用干预措施：醒脑静注射液辅助治疗，且用药疗程至少14 d，对照组及治疗组之间均衡性较好，具有一定可比性，通过简易智力状态检查量表(MMSE)、长谷川痴呆量表(HDS)、日常生活能力表(ADL)、韦氏成人智力量表中的1项或多项进行临床疗效评估。排除除常规治疗外，诊疗方法中还含有对试验结果有显著影响的因素及药物的文献。具体资料，见表1。, 百拇医药(李雨芹 黄顺贵 王思迅 龙秀英)
关键词：醒脑静；血管性痴呆；Meta分析
中图分类号：R749.136 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.026
, http://www.100md.com
文章编号：1006-1959(2018)11-0084-05
Meta Analysis of Efficacy of Xingnaojing Injection in Adjuvant Treatment of Vascular Dementia
LI Yu-qin，HUANG Shun-gui，WANG Si-xun，LONG Xiu-ying
(Department of Neurology，the Sixth People's Hospital of Chengdu，Chengdu 610051，Sichuan，China)
Abstract：Objective To evaluate the efficacy of Xingnaojing injection in the treatment of vascular dementia by meta-analysis. Methods The published literatures on the adjuvant treatment of vascular dementia with Xingnaojing injection were searched in many databases at home and abroad，and the meta-analysis was carried out by screening and applying Review Manager 5.3 in strict articles. Results A total of 12 studies were included， and the analysis showed that Xingnaojing injection assisted the treatment of vascular dementia， and the ratio(OR)of the clinical efficacy was 3.80(95% confidence interval 2.70～5.30).The MMSE score was standardized with a mean difference(SMD)with a combined value of 4.02(95% confidence interval 3.02～5.01).The ADL score was standardized with a mean difference(SMD)with a combined value of 8(95% confidence interval 3.70～12.29).The HDS score was standardized with a mean difference(SMD)with a combined value of 4.08(95% confidence interval 3.46～4.7).Conclusion Xingnaojing injection improved the intelligence，mental state and daily living ability of patients with adjuvant treatment of vascular dementia.The clinical effect is remarkable.
, 百拇医药
Key words：Xingnaojing；Vascular dementia；Meta-analysis
隨着社会的发展，人们对痴呆的认识也逐年提高，老年患者中常见疾病-血管性痴呆，现已成为医务人员的研究热点。血管性痴呆在中医诊断中认为属于“呆病”，研究 [1，2]认为具有“醒脑通窍”作用的醒脑静注射液对于急性脑血管病的治疗有着一定的疗效，起着神经保护作用。基于此，醒脑静注射液辅助治疗血管性痴呆也开始研究，为了系统了解醒脑静注射液治疗血管性痴呆的临床疗效，我们采用Meta分析进行评价，希望为临床用药决策提供参考。
1 资料与方法
1.1 文献查找 应用检索词“醒脑静(Xingnaojing)”，“血管性痴呆(Vascular dementia)”检索1990～2017年PubMed、万方数据库、中国学术网期刊全文数据库、中国维普数据库等，查阅原文并进行统计分析。
1.2文献标准 纳入文献病例要求是依据美国精神病协会1994年修订的《精神障碍诊断与统计手册》(DSM-IV)诊断标准或中华医学会神经病学分会《血管性痴呆诊断标准草案》，并经头颅CT或MRI检查提示脑梗死或广泛脑室周围白质病变的患者，排除合并严重器质性疾病及并发症的患者，采用随机对照试验，病例数至少15例以上，不包含个案报道及无对照的临床试验或描述试验，治疗组采用干预措施：醒脑静注射液辅助治疗，且用药疗程至少14 d，对照组及治疗组之间均衡性较好，具有一定可比性，通过简易智力状态检查量表(MMSE)、长谷川痴呆量表(HDS)、日常生活能力表(ADL)、韦氏成人智力量表中的1项或多项进行临床疗效评估。排除除常规治疗外，诊疗方法中还含有对试验结果有显著影响的因素及药物的文献。具体资料，见表1。, 百拇医药(李雨芹 黄顺贵 王思迅 龙秀英)